Amarin Corp Plc (AMRN)

[sts66]

No need to invent this vast conspiracy story - go back and read what Gershell was actually talking about - he claimed cost of sales would outweigh increase in sales, and more importantly, he thought STRENGTH was going to be a success (oopsie) - he did nothing but get lucky with that $7 PT, had zero clue what Du was going to Du-Du:

https://www.barrons.com/articles/amarin-stock-cardiovascular-drug-competition-vascepa-51574260352

Shares of the biotech firm Amarin was down more than 4% shortly after the market opened on Wednesday as an analyst at Oppenheimer published a particularly bearish take, arguing that the stock, which closed Tuesday at $22.73, will fall to $7 within 18 months.

In the past two weeks, Amarin shares (ticker: AMRN) gained more than 40% before falling slightly. The stock is up 38.4% this month through Tuesday’s close. The gain came before and after a meeting of an advisory committee of the Food and Drug Administration that voted to recommend an expanded label for Vascepa, Amarin’s fish-derived cardiovascular drug.

“We forecast sales growth to underwhelm and heavy selling costs to impede profitability,” Oppenheimer analyst Leland Gershell said in a Tuesday afternoon note initiating coverage of Amarin. Gershell rates the stock Underperform and set a price target of $7.

“We believe that a [roughly] 12-month stream of late stage competitor data starting next month will increasingly weigh on shares as these products, which we believe offer superior profiles, are factored into models,” Gershell wrote. “While some may regard AMRN as a probable M&A target, we see the likelihood of this outcome as only shrinking with time.”